Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics
Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics
The company, based on science from the Hackensack Meridian Center for Discovery and Innovation, promises to capture biomarkers for early diagnostics detecting cancer and a variety of diseases
该公司基于哈肯萨克子午线发现和创新中心的科学，承诺捕获生物标记物，用于癌症和各种疾病的早期诊断
EDISON, N.J., Oct. 4, 2023 /PRNewswire/ -- The Hackensack Meridian Health Research Institute and its Office of Innovation and Commercialization have taken the step of establishing the first spin-off company based on science developed within the Hackensack Meridian Health network. The company aims to make tests detecting cancer and other diseases earlier than ever before.
新泽西州爱迪生，2023年10月4日/美通社/--哈肯萨克子午线健康状况研究院及其创新和商业化办公室采取步骤，建立了第一家以哈肯萨克子午线内发展的科学为基础的剥离公司健康状况网络。该公司的目标是比以往任何时候都更早地进行检测癌症和其他疾病。
EValuate Diagnostics will market a new system for the capture of extracellular vesicles (EVs), including exosomes, which have been elusive to medicine thus far. Novel diagnostic assays derived from this technology will help select and identify disease biomarkers for earlier-than-ever detection of tumors and a wide range of other diseases.
评估诊断公司将推出一种新的系统来捕获细胞外小泡(EV)，包括外体，到目前为止，药物一直难以捉摸这些EV。从这项技术衍生出来的新的诊断分析将有助于选择和识别疾病生物标记物，以便比以往更早地检测肿瘤和广泛的其他疾病。
"This is a remarkable breakthrough for our health network, and for patients of the future," said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health. "We are taking the science produced by our terrific minds at the Hackensack Meridian Health Research Institute, and then moving it to the market so it can benefit all. Detecting deadly cancers as soon as possible means lives can, and will, be saved."
这对我们的健康网络和未来的患者来说都是一个了不起的突破。罗伯特·C·加勒特，哈肯萨克子午线公司首席执行官法希健康状况。“我们正在研究哈肯萨克子午线由我们卓越的头脑产生的科学。健康状况研究机构，然后将其推向市场，使所有人都能受益。尽早发现致命的癌症意味着生命能够并将被拯救。
The company is based upon the work of Olivier Loudig, Ph.D., an associate member of the Hackensack Meridian Center for Discovery and Innovation (CDI), who is directly involved with the development of EValuate Diagnostics. His Laboratory at the CDI has developed research programs for biomarker discovery and early detection of breast, lung, and prostate cancers using liquid biopsies.
该公司基于Hackensack子午线发现和创新中心(CDI)的准成员Olivier LouDig博士的工作，他直接参与了评估诊断的开发。他在CDI的实验室开发了生物标记物发现和使用液体活检早期检测乳腺癌、肺癌和前列腺癌的研究计划。
Developing cancer lesions, which may remain elusive due to their small size by traditional imaging approaches or tissue biopsies, still leave a molecular trace in biofluids such as blood. The laboratory of Dr. Loudig has homed in on this minute trail and, using highly sensitive next-generation-sequencing technologies, has been able to detect RNA signature indicative of the developing lesions. The development of gene expression assays for diagnostics is widely used for evaluating large tumors, but with this novel tracking technology, and applied to early detection has the potential to exponentially help save patient lives.
正在发生的癌症损伤，由于其体积小，在传统的成像方法或组织活检中可能仍然难以捉摸，但在血液等生物体液中仍会留下分子痕迹。劳迪格博士的实验室一直专注于这一微小的追踪，并利用高度敏感的下一代测序技术，已经能够检测到表明病变正在发展的RNA签名。用于诊断的基因表达分析的发展被广泛用于评估大型肿瘤，但利用这一新的跟踪技术，并将其应用于早期检测，有可能成倍地帮助挽救患者的生命。
"We are really establishing the threshold of detection," said Dr. Loudig recently.
“我们真的是在建立检测的门槛，”劳迪格博士最近说。
A core tenet of the mission of the CDI, founded in 2019, is translating cutting-edge science to rapidly impact patient health for New Jersey's largest and most comprehensive health network. EValuate Diagnostics is a direct product of this research ethos, driving the discoveries of the Loudig Laboratory to help patients in the very near future.
CDI成立于2019年，其使命的核心宗旨是将尖端科学转化为快速影响患者健康的新泽西州的最大、最全面的卫生网络。评估诊断是这种研究精神的直接产物，推动了Loudig实验室在不久的将来帮助患者的发现。
"This is a thrilling development," said Sandra Powell-Elliott, the chief innovation officer for Hackensack Meridian Health, who leads the network's Office of Innovation and Commercialization. "The health network supports so many great initiatives - but this is a new way for the health network to really bring innovation to the next level."
“这是一个激动人心的发展，”他说。桑德拉·鲍威尔-埃利奥特，哈肯萨克子午线公司的首席创新官健康状况，他领导着该网络的创新和商业化办公室。医疗网络支持了这么多伟大的举措--但这是医疗网络真正将创新推向下一个层次的新途径。
"This is a new milestone for innovation at Hackensack Meridian Health," said Ihor Sawczuk, M.D., FACS, Hackensack Meridian Health's president of Academics, Research and Innovation, founding chair of the Hackensack Meridian Health Research Institute, and also associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine. "The work of Olivier Loudig is promising, and we want to fulfill that promise with all the support we can provide."
这是哈肯萨克子午线创新的新里程碑健康状况，“说Ihor Sawczuk，医学博士，FACS，Hackensack子午线健康的总裁，学术、研究和创新，哈肯萨克子午线创始主席健康状况他也是哈肯萨克子午线医学院临床整合副院长、泌尿外科教授和名誉主席。奥利维尔·劳迪格的工作前景看好，我们希望尽我们所能实现这一承诺。
The Office of Innovation and Commercialization launched in 2022 and promises to support innovations and discoveries across Hackensack Meridian Health. One of its marquee programs so far is the Bear's Den - an innovation incubator launched in 2017 which brings together a panel of experts, including Hackensack Meridian Health CEO Garrett, leading physicians, key network executives, venture capitalists, patent attorneys, who gather regularly to vet proposals from entrepreneurs. The health network's novel incubator has vetted many products and strategies to streamline care delivery, reduce infections, lower hospital readmissions and help patients partner in their care with physicians. The program has also invested in promising innovative companies.
创新和商业化办公室成立于2022年，承诺支持整个哈肯萨克子午线的创新和发现健康状况。到目前为止，它的一个重要项目是Bear‘s Den，这是一个创新孵化器，于2017年推出，汇集了包括Hackensack Meridian在内的专家小组健康状况首席执行官加勒特、顶尖医生、关键网络高管、风险资本家、专利律师，他们定期聚集在一起审查企业家的提案。该健康网络的新型孵化器已经审查了许多产品和战略，以简化护理提供，减少感染，降低再次住院人数，并帮助患者与医生合作护理。该计划还投资了前景看好的创新公司。
ABOUT HACKENSACK MERIDIAN HEALTH
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care. The network has 18 hospitals and more than 500 patient care locations, which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, rehabilitation centers, urgent care centers, physician practice locations, and a fitness and wellness center. With more than 35,000 team members and 7,000 physicians, Hackensack Meridian Health is a distinguished leader in health care philanthropy and committed to the health and well-being of communities throughout New Jersey.
约哈肯萨克子午线健康状况
哈肯萨克子午线健康状况是一家领先的非营利性医疗保健组织，是全球最大、最全面和真正一体化的医疗保健网络新泽西，提供全方位的医疗服务、创新研究和改善生活的护理。该网络拥有18家医院和500多个患者护理地点，其中包括门诊护理中心、手术中心、家庭健康服务、长期护理和辅助生活社区、救护车服务、救生空中医疗运输、康复中心、紧急护理中心、医生执业地点以及健身和健康中心。拥有超过35,000名团队成员和7,000名医生，哈肯萨克子午线健康状况是医疗保健慈善事业的杰出领导者，致力于整个社区的健康和福祉新泽西。
The network's notable distinctions include having more U.S. News-ranked hospitals than any other health system in New Jersey, as ranked by U.S. News & World Report, 2022-23. Hackensack University Medical Center is nationally-ranked by U.S. News & World Report in four specialties, more than any other hospital in New Jersey. Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, and K. Hovnanian Children's Hospital at Jersey Shore University Medical Center, are ranked #1 in the state and top 20 in the Mid-Atlantic Region by U.S. News & World Report's 2023-24 Best Children's Hospital Report. Additionally, their combined nephrology, urology, cancer, and neurology/neurosurgery programs rank in the top 50 in the United States. To learn more, visit .
该网络的显著区别包括拥有更多美国新闻-医院排名超过其他任何医疗系统新泽西，按以下顺序排列《美国新闻与世界报道》，2022-23年。哈肯萨克大学医学中心在全国范围内排名《美国新闻与世界报道》在四个专科，比其他任何一家医院都要多新泽西。哈肯萨克大学医学中心的约瑟夫·M·桑扎里儿童医院和泽西海岸大学医学中心的K·霍夫纳尼亚儿童医院在该州排名第一，在大西洋中部地区排名前20。《美国新闻与世界报道》2023-24年度最佳儿童医院报告。此外，他们的肾病学、泌尿科、癌症和神经病学/神经外科课程在美国。要了解更多信息，请访问。
ABOUT THE CENTER FOR DISCOVERY AND INNOVATION
关于发现和创新中心
The Center for Discovery and Innovation, a member of Hackensack Meridian Health, translates current innovations in science to improve clinical outcomes for patients. More than 29 laboratories, 185 professional researchers and physician-scientists at the CDI have set their sights on cancer, infectious diseases, autoimmune disorders, and other acute and chronic diseases. Clinical need drives the scientific insights, and their application, for these researchers, as shown in the real-time response to the COVID-19 pandemic, resulting in new diagnostics, therapies, and surveillance abilities. The CDI leverages a new wave of scientific advances involving genetics, cell engineering of the human immune system, and imaging to better diagnose, treat and prevent disease through personalized medicine approaches. For additional information, please visit .
Hackensack子午线健康中心的成员之一，发现和创新中心，将当前的科学创新转化为改善患者的临床结果。CDI的29个实验室、185名专业研究人员和内科科学家将目光投向了癌症、传染病、自身免疫性疾病和其他急慢性疾病。临床需求推动了这些研究人员的科学见解及其应用，正如对新冠肺炎大流行的实时反应所显示的那样，从而产生了新的诊断、治疗和监测能力。CDI利用涉及遗传学、人类免疫系统细胞工程和成像的新一波科学进步，通过个性化医学方法更好地诊断、治疗和预防疾病。欲了解更多信息，请访问。
ABOUT HACKENSACK MERIDIAN HEALTH RESEARCH INSTITUTE (HMHRI):
HMHRI leads and organizes a connected ecosystem bringing together clinicians, scientists, and educators to respond to the health problems of our time, in real-time. HMHRI is dedicated to accelerating discovery, innovation, and translation of scientific breakthroughs that address unmet clinical needs.
约哈肯萨克子午线健康研究所(HMHRI)：
HMHRI领导和组织一个互联的生态系统，将临床医生、科学家和教育工作者聚集在一起，实时应对我们这个时代的健康问题。HMHRI致力于加速发现、创新和转化解决未满足的临床需求的科学突破。
SOURCE Hackensack Meridian Health
来源：Hackensack子午线健康